Stocks › SRPT
Sarepta Therapeutics, Inc.
SRPT·Nasdaq·
United States·USD
United States·USD$17.50
+0.19 (+1.10%)
Close · Oct 7, 2026 · Close Prices from Tiingo.com
SRPT
Sarepta Therapeutics, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
SRPTS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of SRPT by members of U.S. Congress · 18 on record
Whale Activity
Position changes in SRPT reported for 2026-06-30 by 13 tracked institutional filers
- Increased5
- New1
- Held1
- Decreased2
- Closed2
- No prior filing2
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 19.0M | $341.3M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 8.4M | $150.5M | increased |
| TWO SIGMA INVESTMENTS, LP | 4.6M | $82.6M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.6M | $82.5M | increased |
| MILLENNIUM MANAGEMENT LLC | 1.2M | $21.4M | decreased |
| RENAISSANCE TECHNOLOGIES LLC | 1.1M | $20.2M | decreased |
| D. E. Shaw & Co., Inc. | 16.9M | $15.9M | held |
| Point72 Asset Management, L.P. | 510.9K | $9.2M | new |
| Casdin Capital, LLC | 470.0K | $8.4M | — |
| Bridgewater Associates, LP | 152.1K | $2.7M | increased |
| One68 Global Capital, LLC | 15.8K | $284K | — |
| Citadel Advisors LLC | 0 | $0 | closed |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by SRPT insiders, by quarter · Form 4
Recent Insider Transactions
651 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Boor Kathryn JeanDirector | Grant / award | +16.9K | — | — | Jun 4, 2026 | Form 4 ↗ |
| Mayo StephenDirector | Grant / award | +16.9K | — | — | Jun 4, 2026 | Form 4 ↗ |
| Wigzell Hans Lennart RudolfDirector | Grant / award | +16.9K | — | — | Jun 4, 2026 | Form 4 ↗ |
| BEHRENS M KATHLEENDirector | Grant / award | +16.9K | — | — | Jun 4, 2026 | Form 4 ↗ |
| Connelly Deirdre PDirector | Grant / award | +16.9K | — | — | Jun 4, 2026 | Form 4 ↗ |
| Nicaise ClaudeDirector | Grant / award | +16.9K | — | — | Jun 4, 2026 | Form 4 ↗ |
| Chambers Michael AndrewDirector | Grant / award | +16.9K | — | — | Jun 4, 2026 | Form 4 ↗ |
| Barry RichardDirector | Grant / award | +16.9K | — | — | Jun 4, 2026 | Form 4 ↗ |
| Mayo StephenDirector | Sale | −7,239 | $17.02 | $123K | Mar 12, 2026 | Form 4 ↗ |
| Estepan Ian MichaelChief Operating Officer | Tax withholding | −1,097 | $17.03 | $19K | Mar 11, 2026 | Form 4 ↗ |
| Wong Ryan Ho-YanChief Financial Officer | Tax withholding | −256 | $17.03 | $4K | Mar 11, 2026 | Form 4 ↗ |
| Rodino-Klapac LouisePresident, R&D and Tech Ops | Tax withholding | −948 | $17.03 | $16K | Mar 11, 2026 | Form 4 ↗ |
| Rothfuss CristinEVP, General Counsel | Tax withholding | −974 | $17.03 | $17K | Mar 11, 2026 | Form 4 ↗ |
| Wong Ryan Ho-YanChief Financial Officer | Tax withholding | −113 | $16.95 | $2K | Mar 9, 2026 | Form 4 ↗ |
| Wong Ryan Ho-YanChief Financial Officer | Tax withholding | −162 | $16.95 | $3K | Mar 9, 2026 | Form 4 ↗ |
| Rothfuss CristinEVP, General Counsel | Tax withholding | −346 | $16.95 | $6K | Mar 9, 2026 | Form 4 ↗ |
| Rothfuss CristinEVP, General Counsel | Tax withholding | −484 | $16.95 | $8K | Mar 9, 2026 | Form 4 ↗ |
| Rodino-Klapac LouisePresident, R&D and Tech Ops | Tax withholding | −895 | $16.95 | $15K | Mar 9, 2026 | Form 4 ↗ |
| Rodino-Klapac LouisePresident, R&D and Tech Ops | Tax withholding | −504 | $16.95 | $9K | Mar 9, 2026 | Form 4 ↗ |
| Estepan Ian MichaelChief Operating Officer | Tax withholding | −583 | $16.95 | $10K | Mar 9, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding SRPT · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF iShares Trust | 6.4M | $114.3M | 0.10% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 4.5M | $80.2M | 0.75% | Jun 30, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund First Trust Exchange-Traded Fund | 3.6M | $64.4M | 2.29% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 3.2M | $57.3M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 2.7M | $48.5M | 0.06% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 2.3M | $41.3M | 0.02% | Jun 30, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 1.3M | $24.0M | 0.05% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.2M | $21.6M | 0.02% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF SPDR SERIES TRUST | 968.2K | $17.4M | 0.10% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 1.1M | $16.9M | 0.05% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list SRPT's shares (CUSIP 803607100), each fund at its latest report since Mar 8, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- AQR Capital Management Holdings, LLCSCHEDULE 13G/A · passive (13G) · 5.3M shares5.0%
Aug 13, 2026 · ↗ - AQR Capital Management, LLCSCHEDULE 13G/A · passive (13G) · 5.3M shares5.0%
Aug 13, 2026 · ↗ - SSGA FUNDS MANAGEMENT, INC.SCHEDULE 13G · passive (13G) · 6.3M shares6.0%
Aug 7, 2026 · ↗ - STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 8.9M shares8.4%
Aug 7, 2026 · ↗ - Vanguard Portfolio ManagementSCHEDULE 13G/A · passive (13G) · 8.5M shares8.1%
Jul 31, 2026 · ↗ - BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 16.6M shares15.8%
Jul 30, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming sarepta therapeutics as client
- MICHAEL BEST STRATEGIES LLCSAREPTA THERAPEUTICS · 2026 Q2 · HCR, MED$50K
Filing ↗ - TARPLIN, DOWNS & YOUNG, LLCSAREPTA THERAPEUTICS · 2026 Q2 · BUD, HCR, MMM$90K
Filing ↗ - SAREPTA THERAPEUTICS, INC.SAREPTA THERAPEUTICS, INC. · 2026 Q2 · BUD, HCR, SCI, TRD$220K
Filing ↗ - MICHAEL BEST STRATEGIES LLCSAREPTA THERAPEUTICS · 2026 Q1 · HCR, MED$110K
Filing ↗ - SAREPTA THERAPEUTICS, INC.SAREPTA THERAPEUTICS, INC. · 2026 Q1 · HCR, SCI$270K
Filing ↗
Government Contracts
Federal awards to Sarepta Therapeutics, Inc. · USAspending
No federal contract awards found for Sarepta Therapeutics, Inc..
U.S. Patents
Recent USPTO applications naming Sarepta Therapeutics, Inc.
No USPTO patent applications found for Sarepta Therapeutics, Inc..
Annual Financials
From SRPT's 10-K filings · XBRL
No annual XBRL figures on record for SRPT. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
- 1-for-6Reverse splitJul 12, 2012
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 1.01Material agreementSep 23, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 5, 2026
EDGAR ↗ - 8-K · Items 5.02, 7.01, 9.01Officer / director change · Reg FD disclosureJul 27, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteJun 4, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 6, 2026
EDGAR ↗
About Sarepta Therapeutics, Inc.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersCAMBRIDGE, MA
IncorporatedDE
SEC CIK0000873303 ↗
Former namesSarepta Therapeutics, Inc., AVI BIOPHARMA INC, ANTIVIRALS INC